None listed
Conditions
Brief summary
In this study we aim to collect dental, saliva, blood and stool samples to characterise the gut microbiome profile of individuals with cardiovascular disease, specifically heart failure patients which include those requiring placement of a ventricular assist device or a heart transplant and compare their microbiome profile to that of healthy individuals. Individuals with cardiovascular disease will have an alteration in the composition and functionality of their gut microbiome compared to healthy individuals.
Interventions
Heart failure is a chronic condition, with symptoms such as shortness of breath, fatigue, dizziness and oedema, and signs, such as increased venous pressure and pulmonary crackles, occurring when the heart cannot pump blood effectively around the whole body due to a weak or stiff heart muscle. The aim of this study is to profile the gut microbiome, from dental scrapings, saliva, blood and faecal samples in people with acute coronary syndrome, chronic stable angina and healthy individuals. This is important as many studies have established that normal people have a certain gut microbiome profile compared to people with cardiovascular disease. In addition to gut microbiome profiling, the information gathered from the results of this study may be beneficial in a clinical setting. Given the prevalence of cardiovascular disease and the large interest in the microbiome field, the findings of this study will allow a greater understanding of the role of the microbiome in cardiovascular disease, which will have important clinical implications. It may also facilitate the future development of different therapeutic strategies to target and/or change the microbiome, which will be explored through intervention studies. Dental, stool, saliva and blood samples will be obtained in the hospital at baseline (time zero) and again at follow-up (6 months).
Sponsors
Eligibility
Inclusion criteria
Men and women between 40– 80 years of age presenting to Fiona Stanley Hospital with heart failure will be recruited for the study. Healthy family members of patients will be invited to take part in the study and will act as environmental controls and will be age matched where possible. Inclusion criteria: • The participant to present to FSH with heart failure • Healthy participants will be relatives of heart failure patients and are defined as individuals with no clinically relevant abnormalities identified by a detailed medical history, full physical examination including blood pressure, heart rate, clinical lab tests from a fasting blood sample • Evidence of a personally signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the trial • Willing and able to comply with study procedures, i.e. sample collection
Exclusion criteria
Participants will be excluded from the study: • If there are circumstances that interfere with the participant’s ability to give informed consent (e.g. diminished understanding, or proficiency in English language and an interpreter unavailable) • Participants taking probiotics, antibiotics or antivirals which may disrupt gut microbiota environment, current or recent <3 months. • Major chronic disease e.g. cancer or dementia • Healthy participants will be excluded if they have a history of major chronic disease (including cardiovascular disease, psychiatric illness, cancer, diabetes), BMI <18 or >35 kg/m2, current or recent (<12 months) smoking, current or recent (<6 months) significant weight loss or gain (>6% body weight), alcohol intake >280g p/week for men and >210g p/week for women. • Inability to comply with study procedure